Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2000

View Archived Issues

Clinical trials of cancer gene therapy begin at Cobra Therapeutics

ADCON-T/N effective in tendon and peripheral nerve surgeries

Incyte and Baylor collaborate on genomic cancer research in children

Myriad Genetics to use investment funds for colon cancer research

IntraBiotics begins phase III clinical study of ramoplanin

Commencement of phase II trials of WF-10 in hepatitis C announced

Theratechnologies moves forward with PDT development program

Biogen gains rights to neublastin for non-CNS indications

Cell Pathways reports positive one-year extension data from phase III Aptosyn study

Biovail completes development of controlled-release formulation of Celexa

Celgene to acquire Signal

TAP withdraws Uprima NDA until further data available

Idec and Taisho to develop antibodies targeting inflammatory and autoimmune diseases

CPMP adopts positive opinion for new pediatric vaccines from SB

VX-497 plus interferon alfa enters phase II for the treatment of HCV

Inhibitors of dual-specificity phosphatases inhibit growth of breast cancer cells

Retinoid-like effects of R-115866 characterized in preclinical studies

KNK-437: a novel inhibitor of the development of thermotolerance and HSP induction in cancer cells

European investigators report immunomodulatory antiarthritic effects for HS-378

Design of synthetic leptin agonists derived from mouse leptin sequence reported at ENDO 2000

First mechanism-based MMP inhibitor designed at Wayne State as potential anticancer agent

HGS reports new chemokine polypeptides

Identification and potential uses of novel chemokine revealed by U.S. researchers

Alcon claims use of AIT-082 and other neurotrophic factor enhancers in ophthalmic disorders

Sibutramine demonstrates efficacy in urinary incontinence

Innogenetics patents immunotoxins for use in immune disorders and certain malignancies

New compounds from Banyu block M3 receptors, prove effective in canine model of bronchoconstriction

2-Oxoimidazoles as ligands for ORL1 (N/OFQ) receptors

Inhibitors of IL-5 production disclosed in patent literature by Janssen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 1, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026